WO2004014930A1 - 選択的なアリール5−チオ−β−D−アルドヘキソピラノシドの製造法 - Google Patents
選択的なアリール5−チオ−β−D−アルドヘキソピラノシドの製造法 Download PDFInfo
- Publication number
- WO2004014930A1 WO2004014930A1 PCT/JP2003/010159 JP0310159W WO2004014930A1 WO 2004014930 A1 WO2004014930 A1 WO 2004014930A1 JP 0310159 W JP0310159 W JP 0310159W WO 2004014930 A1 WO2004014930 A1 WO 2004014930A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- alkoxy
- substituted
- halogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
Definitions
- the present invention relates to a process for producing aryl 5-thio] 3-D- : by ⁇ selective darkosylation.
- Phlorizin a glucose derivative isolated from nature, has been shown to inhibit the reabsorption of excess glucose in the kidney, promote glucose excretion and have hypoglycemic effects (J. Clin. Inves t., Vol. 80, pp. 1037, 1987; Vol. 87, pp. 1510, 1987). Later, it was clarified that this glucose reabsorption was due to the sodium-dependent glucose transporter 2 (SGLT2) present at the S1 site in the renal proximal tubule (J. Clin. Invest. 397, 1994).
- SGLT2 sodium-dependent glucose transporter 2
- 5-thioaldopyranose which is a glucose analog, in which the ring oxygen atom of aldoviranose is converted to a sulfur atom.
- 5-thioaldopyranose has different biochemical properties than aldopyranoses.
- An object of the present invention is to provide a novel method for producing an aryl-5-thio-j3-D-aldohexovyranoside derivative selectively.
- aryl 5-thio j3-D-darcoviranoside inhibits the activity of the sodium-dependent glucose transporter (SGLT 2) involved in glucose reabsorption in the kidney and promotes urinary glucose excretion, thereby lowering blood glucose. It is expected to show action.
- SGLT 2 sodium-dependent glucose transporter
- the present inventors have failed to achieve the above object by applying various known glycosylation reaction conditions as shown in Reference Examples described later, but surprisingly, it has been found that the [3-selection in 5-thio-L-arabinose] When the conditions of the Mitsunobu reaction without carbohydrate glycosylation (Carbohydr. Res., Vol. 311, para. 191, 1998) are applied to thioaldohexopyranois], 3-selective glycosylation occurs and 5- The present inventors have discovered that a 6-D-aldohexopyranoside derivative can be selectively synthesized and completed the present invention.
- the present invention provides an aryl-5-thio D useful as an SGLT2 inhibitor by reacting a 5-thio_D-aldoxopyranoyl derivative with a hydroxyaryl derivative in the presence of a phosphine.
- the present invention provides a method for producing an aldohexoviranoside derivative or a synthetic intermediate thereof.
- the present invention provides a phosphine represented by PRRR 13 and a phosphine represented by PRRR 13 by converting a 5-thio D-aldohexopyranose derivative of the formula (I) and Ar—OH of the formula (II) according to the following scheme.
- 2 1 — N N —
- R 2 2 the aryl-5-thio / 3-D-aldoxo of the formula (III) is obtained.
- the wavy line means that it contains any of the stereoisomers of the D-form, the L-form and the mixture,
- Y is one O— or one NH—
- RK R 2 , R 3 and R 4 are the same or different
- R 1 and R 2 , R 2 and R 3 or R 3 and R 4 combine to form one C (R B )-(R A and R B are the same or different, and Atom, which is a 6 alkyl or phenyl group).
- Ar is an aryl group which may be substituted with an arbitrary substituent (where the substituent means a substituent which does not participate in the reaction),
- R 11 ⁇ R 13 are the same or different and represent a C i _ 6 alkyl a phenyl group which may be substituted with a group, a pyridyl group or an alkyl group,
- R 21, R 22 are identical or different, C 2 - shows a 4 Arukiruamino force Ruponiru group or Piperijinokarupo two Le group - 5 alkoxycarbonyl Cal Poni Le group, N, N-di ⁇ .
- the present invention preferably comprises
- a 1 is an aryl group which may be substituted with the same or different 1 to 4 substituents, and the substituent is a halogen atom; a hydroxyl group; one + NH 3 ;-+ ⁇ (CH 3 ) 3; A C 6 alkyl group optionally substituted with 1 to 4 substituents selected from the group consisting of an atom and a hydroxyl group;
- m is an integer of 0 to 4
- Q is a formyl group; amino group; nitro group; cyano group; carboxyl group; sulfonic acid group; which may be substituted with 1 to 4 halogen atoms - 6 alkoxy group; CI- C6 alkoxy 6 alkoxy groups; C 2 - 10 ⁇ shea Ruokishi groups; C 2 ⁇ .
- substituents may be substituted, C 3 _ 7 cycloalkyl; C 3 _ 7 Shikuroa Rukiruokishi group; Ariru group; C 7 - i. Aralkyl group; aryloxy group; ⁇ —i. Ararukiruokishi group; C 7 _ 10 Ararukiruamino group; Heteroariru group or 4 in 6-membered heterocycloalkyl group (wherein the substituents are halogen atom, Taukappa group, It is selected from the group consisting of one X- A 2; ( ⁇ _ 6 alkyl Moto ⁇ Pi is selected from the group consisting of _ 6 alkoxy group)
- m ′ is an integer of 0 to 4
- C 3 _ 7 cycloalkyl C 3 7 Shikuroa Rukiruokishi group; ⁇ Li Ichiru group; C 7 _ i 0 Ararukiru group; Ariruokishi group; C 7 _ x . C 7 — i0 aralkylamino group; heteroaryl group or 4- to 6-membered heterocycloalkyl group (where the substituent is selected from the group consisting of a halogen atom, a hydroxyl group, an alkyl group and an alkoxy group. ) Is provided.
- the present invention preferably comprises
- Formula (I) is represented by the above formula (IV) (the definitions of RR 2 , R 3 and R 4 are as described above), and formula (III) ′ is represented by the above formula (V) (A 1 , RK R 2 , R 3 and R 4 are as defined above).
- a 1 is a phenyl group substituted by one X—A 2 (the definitions of X and A 2 are as defined above), wherein the phenyl groups are further identical or different. May be substituted by one to three substituents,
- the substituent include a halogen atom; 7K group; 1-4 amino which may be substituted with a substituent C i _ 6 alkyl group selected from halogen atom and the group consisting of a hydroxyl group;
- a 1 has the following formula:
- X is one (CH 2 ) n-, -CO (CH 2 ) n-, -C (OH) (CH 2 ) n one,-O-(CH 2 ) n-, -CONH (CH 2 ) n-, one NHCO (CH 2 ) n
- N is an integer of 0-3), —COCHCHCH—, —S— or —NH—, wherein R 3Q , R 31 , R 32 and R 33 are the same or different,
- Hydrogen atom a halogen atom, a hydroxyl group; 1-4 amino which may be substituted with a substituent C _ 6 alkyl group selected from halogen atom and the group consisting of a hydroxyl group;
- m is an integer of 0 to 4
- Q is a formyl group; an amino group; a nitro group; a cyano group; a propyloxyl group; a sulfonic acid group; 6 alkoxy groups; — 6 alkoxy C ⁇ — 6 alkoxy groups; C 2 —.
- C 3 - 7 cycloalkyl group C 3 _ 7 Shikuroa Rukiruokishi group; Ariru group; C 7 _ 10 Ararukiru group; Ariruokishi group; C ⁇ ?.
- R 4Q , R 41 , R 42 , R 43 and R 44 are the same or different,
- Hydrogen atom halogen atom
- hydroxyl group selected from the group consisting of a halogen atom and a hydroxyl group
- An alkyl group which may be substituted with 1 to 4 substituents;
- m ′ is an integer of 0 to 4
- a 1 is preferably a group represented by the following formula:
- R 3QA , R 31A , R 32A and R 33A are the same or different,
- m A is an integer of 0 to 4
- Q A is a formyl group; a carboxyl group; 1-4 amino alkoxy group optionally substituted by a halogen atom; ⁇ - 6 alkoxy alkoxy group;. 2 ⁇ .
- C 3 - 7 cycloalkyl group May be substituted with 1-4 substituents, C 3 - 7 cycloalkyl group; C 3 _ 7 Shikuroa Rukiruokishi group; ⁇ Li Ichiru group; C 7 - 10 Ararukiru group; ⁇ Li one Ruokishi groups; C ? ⁇
- R40, R 41, R 42, definitions of R43 and R44 is the above method represented by are as defined above]. More preferably, the compound of formula (V) has the following formula:
- R 3 ° B to R 33B may be the same or different, and represent a hydrogen atom, a halogen atom,
- R C is a hydrogen atom, halogen atom, C - 6 alkyl group, ( ⁇ - 6 alkoxy group, hydroxy ⁇ - 4 alkyl group, one 6 alkyl Le group substituted with a halogen atom or a (: a preparative 6 alkylthio group, R 4A is a hydrogen atom a C 2 _ 6 Arukokishikaru Poniru group or C 2 _ 6 Al force Noiru group, R 1 a ⁇ R 3 a is identical or different connexion may, hydrogen atom, c 2 - 8 Arukanoiru group or Benzoiru group is there) It is a compound represented by these. More preferably, the compound of formula (V)
- R D is a hydrogen atom, a halogen atom, an (alkyl or hydroxyalkyl group
- R E represents a hydrogen atom, a halogen atom, a (6 alkyl group, ⁇ alkoxy group or a hydroxyalkyl d_ 4 alkyl group
- Ar (and A 1 ) is an aryl group substituted with 1 to 4 electron withdrawing groups, wherein A 1 is a group represented by the formula (VI) If (VI I) represented by and (VI I 1)) is one even without less of R 3Q to R 33 (and R 3QA ⁇ R 33A and R 3QB ⁇ R 33B) is an electron withdrawing group Preferably, there is.
- electron withdrawing group refers to a substituent that is more likely to attract an electron from the bond atom side than a hydrogen atom, and is the sum of the substituent effects such as the induction effect ⁇ the mesomeric effect (or resonance effect). Means to attract electrons.
- Typical examples include a formyl group, a nitro group, Shiano group, forces Rupokishiru group, scan sulfonic acid group, One + NH 3, One + N (CH 3) 3, - CF 3, one CC1 3, One COCH 3, One CO 2 CH 3 , one CO 2 C 2 H 5 , one COPh, —SO 2 CH 3 and a halogen atom.
- the substitution position is preferably ortho, Z, or para to the OH group of aryl alcohol.
- the darcosylation reaction can be performed in high yield. This is thought to be because the acidity of the aryl alcohol to be darcosylated greatly contributes to the reaction yield in this reaction.
- an electron withdrawing group is introduced into the aryl group to be darcosylated, a darcosylation reaction is performed, and then the electron withdrawing group is removed by catalytic hydrogenation, hydrolysis, decarboxylation, or the like, or is known to those skilled in the art.
- the desired aryl-5-thio) 3-D-aldoxopyranoside derivative can be obtained in high yield by converting to another substituent using the method (for example, reduction).
- the halogen atom can be removed by catalytic hydrogenation.
- R 1 1 ⁇ R 1 3 are the same or different connexion,
- C i _ 6 alkyl group Invite example good phenyl group (e.g. substituted , A phenyl group, a tolyl group), a pyridyl group, and a ⁇ -e alkyl group (for example, a methyl group, an n-butyl group, or a t-butyl group).
- Preferred examples of the phosphines include triphenyl phosphine, tri-n-butyl / phosphine, tri-t-butyl phosphine, and tolyl phosphine diphenyl-2-pyridyl phosphine. Of these, triphenylphosphine and diphenyl-1-pyridylphosphine are preferred, and triphenylphosphine is more preferred.
- R 2 1 - N N- ⁇ zo reagent represented by R 2 2"
- R 2 1, R 2 2 are the same or different, C 2 _ 5 alkoxy Cal Poni Le group, ⁇ , ⁇ - di alkylamino It represents a carbonyl group or a piperidinocarbonyl group.
- Preferred examples of the azo reagent include getyl azodicarboxylate, diisopropylpropyl azodicarboxylate di-tert-butyl azodicarboxylate, 1,1,1-azobis (N, N-dimethylformamide) ), ⁇ , ⁇ - (azodicarponyl) dipiperidine and the like. Among them, getyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate and the like can be mentioned.
- the solvent used in this reaction is tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, acetonitrile, ethyl acetate, dimethyl sulfoxide, N, N-dimethylformamide, etc., preferably tetrahydrofuran, toluene And more preferably toluene.
- the reaction temperature is preferably ⁇ 2 (TC to room temperature).
- the starting materials used in this reaction may be commercially available products or may be synthesized as described below.
- the 5-thio D-aldohexopyranose derivative represented by the formula (I) can be produced, for example, as follows by describing 5-thio D-dalcoviranose (IV) as an example.
- Pen-Yuichi O-acetate derivative (B) (Tetrahedron Lett., Vol. 22, 5061, 1981, J. Org. Chem., Vol. 31, 1514, 1966) is D-Dalcofurano-1 3, It can be synthesized from 6-lactone ( ⁇ ) in 8 steps.
- compound (II) is treated with hydrazine acetate (Tetrahedron, Lett., Vol. 33, Section 7675, 1992) or benzylamine, preferably methyl, in an appropriate solvent (DMF, THF, methanol, ethanol, etc.).
- the compound (C) can be produced by reacting with a 1: 1 mixture of hydrazine and acetic acid to selectively deprotect the 1-acetyl group.
- the reaction temperature ranges from room temperature to 80 ° C, and the reaction time ranges from 20 minutes to 24 hours.
- Ar—OH of the formula (II) and Ai—OH of the formula (II) ′ corresponding to aglycone can be synthesized in the case of a phenol derivative with reference to the following documents: International Patent Publication No. TO0168660, TO0174834 No., W00174835, TO0228872, W00244192, Ran 64606, W00311880.
- a 1 of A 1 — ⁇ H is represented by the formula (VI) and X is —CH 2 — can be obtained by converting a phenol derivative and a benzyl alcohol derivative under acidic conditions. It can also be produced by condensation.
- Examples of the acid used in the condensation include methanesulfonic acid and p-toluenesulfonic acid.
- a solvent a high boiling point solvent such as nitrobenzene is preferable.
- the reaction temperature is 100 ° C-200, and the reaction time is 10 minutes-150 minutes. After the completion of this reaction, the protecting group for the sugar hydroxyl group can be further deprotected, if necessary.
- bases such as sodium methoxide, sodium hydroxide, lithium hydroxide, potassium carbonate, cesium carbonate, and triethylamine can be used.
- Suitable solvents for the reaction are methanol, ethanol, hydrated methanol and the like. The terms used in the present invention is defined below (in the definition, the "C x _y" indicates that subsequent groups having X- y carbon atoms).
- the “5-thio-D-aldohexopyranose derivative” means a sugar analog in which the oxygen atom at the 5-position of aldopyranose, that is, the ring oxygen atom is replaced with a sulfur atom.
- 5-thio D-crecopyranose 5-thio D-galactopyranose
- 5-thio D-galactopyranose Carbohydr. Res., Vol. 76, paragraph 165, 1979
- 5-thio-D-mannopyranoose I. Carbohydr. Chem. , Vol. 8, pp. 753, 1989
- 2-deoxy 2-amino-5-thio D-darcopyranose 2-dexoxy 2-amino-5-thio D-galactopyranose
- RR 2, R 3 and R 4 are hydrogen atom, C 2 - 10 Ashiru group (eg example, Asechiru group, a pivaloyl group, etc. Benzoiru group), if the alkyl group (eg, methyl group, Echiru group), C 7 _ 10 Ararukiru group (e.g., benzyl group), 0, _ 6 alkoxy C 7 _ 10 Ararukiru group (e.g., p- methoxybenzyl group), Ariru group, trialkyl) silyl group (e.g., trimethylsilyl group , Toryechirushi Lil group, t one heptyl dimethylsilyl group), C ⁇ - 6 the alkoxy alkyl group (eg, a main Bok Kishimechiru group).
- alkyl group eg, methyl group, Echiru group
- C 7 _ 10 Ararukiru group e.g., benzyl group
- R 1 and R 2 , R 2 and R 3 or R 3 and R 4 are combined, and one C (R A ) (R B )-(R A and R B are same or different, a hydrogen atom, can form a ( ⁇ _ 6 alkyl group or a phenyl group), and examples thereof include a Asetaru group, Isopuropiriden group and downy Njiriden group.
- the “aryl group” includes a phenyl group and a naphthyl group (including a 1-naphthyl group and a 2-naphthyl group), and preferably represents a phenyl group.
- the "C 2 _ 1Q Ashiru group"' a linear or branched aliphatic Ashiru group having a carbon number of 2-10 (preferably, a C 2 _ 6 Arukanoiru group) and aromatic Ashiru group Meaning includes, for example, an acetyl group, a propionyl group, a piperoyl group, a ptyryl group, an isobutyryl group, a valeryl group, a benzoyl group and the like, among which the acetyl group is preferable.
- 0 ⁇ 6 alkyl group means a linear or branched alkyl group having 1 to 6 carbon atoms, such as a methyl group, an ethyl group, a? -Propyl group, an isopropyl group, Examples include monobutyl group, isobutyl group, er-butyl group, sec-butyl group, monopentyl group, ier-amyl group, 3-methylbutyl group, neopentyl group, and the like.
- C 7 —aralkyl group refers to an arylalkyl group having 7-10 carbon atoms, for example, a benzyl group and a phenylethyl group.
- ( ⁇ - 6 alkoxy group” means a straight or branched ⁇ alkoxy group having 1 one 6 carbon atoms, an alkoxy group is preferable ⁇ - as 4 alkoxy group. Examples thereof include a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, an n-butoxy group, an isobutoxy group, and a tert-butoxy group.
- a "tri (C- 6 alkyl) silyl group” is a group in which three hydrogen atoms are
- Examples include a trimethylsilyl group, a triethylsilyl group, and a t-butyldimethylsilyl group.
- the “ ⁇ -6 alkoxyalkyl group” has a form in which a —6 alkoxy group and an alkyl group are combined, and includes, for example, a methoxymethyl group.
- Halogen atom includes a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.
- the “ 6 alkyl group substituted with 1 to 4 halogen atoms” refers to an alkyl group in which a hydrogen atom on the group is substituted with 1 to 4 halogen atoms (preferably, a fluorine atom). Examples thereof include a trifluoromethyl group, a 1,1,1-trifluoroethyl group, a 1,1,1 trifluoropropyl group, and a 1,1,1-trifluorotrifluoro group. Of these, a trifluoromethyl group and a 1,1,1-trifluoroethyl group are preferred.
- a 6- alkyl group substituted with 1 to 4 hydroxyl groups refers to an alkyl group in which a hydrogen atom on the group has been substituted with 1 to 4 hydroxyl groups, and is preferably substituted with 1 hydroxyl group.
- has been C t - 6 hydroxyalkyl group is an alkyl group, more preferably a hydroxy ⁇ _ 4 alkyl group. Examples include a hydroxymethyl group, a hydroxyethyl group (such as a 1-hydroxyethyl group), a hydroxypropyl group, and a hydroxybutyl group.
- 1-4 C ⁇ substituted with a halogen atom - 6 alkoxy group refers to an alkoxy group in which a hydrogen atom on the group is substituted by a halogen atom.
- examples thereof include a trifluoromethoxy group, a 1,1,1 trifluoroethoxy group, a 1,1,1-trifluoropropoxy group, and a 1,1,1-trifluorobutoxy group.
- a trifluoromethoxy group and a 1,1,1-trifluoroethoxy group are preferred.
- 6 alkoxy 6 alkoxy group for example, such as methoxymethoxy group.
- the ". C 2 ⁇ Ashiruokishi group” has the form C 2 _ 1 0 Ashiru group and one O- were combined, preferably, c 2 - 6 alkanoyloxy noisy Ruo alkoxy group (e.g., Asechiruoki sheet group ), Benzoyloxy group.
- the "C 2 _ 6 alkoxy Cal Poni Le group” has a structure composed of a linear or branched C Bok 5 an alkoxy group and a carbonyl group, preferably, c 2 _ 5 alkoxy Kishikaruponiru And a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group, and the like. Of these, a methoxycarbonyl group is preferable.
- alkylthio group is intended to mean a structure linear or branched alkyl group and one Chio groups (one S-) is complexed with 1 one six carbon atoms, Al Kiruchio group Is preferred.
- alkylthio group include a methylthio group, an ethylthio group, and a propylthio group.
- Alkylsulfinyl group "- 6 alkyl group and Surufieru group (one SO -) has a structure composed of methane sulfide El group, ethanesulfinyl group.
- Alkylsulfonyl group "C i _ 6 alkyl group and a sulfonyl group (an S0 2 -) has a structure composed of, methanesulfonyl group, arbitrarily favored ethanesulfonyl group.
- ⁇ 2 _ 1 () acylamino group is c 2 ⁇ . It has a form in which an acetyl group and an amino group are combined, and an acetylamino group is preferred.
- the “ 6 alkylsulfonylamino group” has a form in which an alkylsulfonyl group and an amino group are combined.
- a methanesulfonylamino group, a ethanesulfonylamino group and the like can be mentioned.
- ⁇ 6 alkylamino group ( ⁇ _ 6 alkyl group and an amino group has a structure composed of. For example, like Mechiruamino group Ya Echiruamino group.
- An “N, N-di-6alkyl) amino group has a form in which two —6alkyl groups and an amino group are combined. For example, a dimethylamino group and a getylamino group are exemplified.
- N-alkyl) aminocarbonyl group has a complex form of an N——6alkyl) amino group and a carbonyl group, and is preferably an N— (C 4 alkyl) amino group. And N-methylaminocarbonyl group.
- N N- di (C ⁇ e alkyl) Aminokaruponiru group
- N has a structure composed of a N- di ((6 alkyl) Amino group and a carbonyl group, preferably, N, N- A di (C i alkyl) aminocarbonyl group, such as an N, N-dimethylaminocarbonyl group;
- Q, ⁇ Q 'and Q A is an alkoxy group include methoxymethyl group.
- Q and Q ′ are amino groups, examples thereof include an aminomethyl group.
- Q, Q ′ and Q A are C 2 _ 1 () acyloxy groups, examples thereof include an acetyloxymethyl group and a benzoyloxyshetyl group.
- Q when Q 'and Q A is C 2 ⁇ 0 Ashiruamino groups like ⁇ cetyl amino methylation group.
- N-di (C ⁇ 6 alkyl) amino groups examples include N, N-dimethylaminoamino groups.
- C 3 _ 7 cycloalkyl group a cyclic alkyl group of 3-7 ⁇ carbon atoms and meaning taste, for example, cyclopropyl group, cyclobutyl group, cyclopentyl group and cyclohexyl group cyclohexylene. Among them, a cyclopropyl group is preferred.
- the “aryloxy group” has a form in which an aryl group and _ ⁇ _ are combined, and examples thereof include a phenoxy group and a naphthoxy group.
- Ararukiruokishi group "has the form c 7 _ 1 0 Ararukiru group and one ⁇ - were combined, for example, Benjiruokishi group and a phenylpropyl E chill O alkoxy group.
- C 7 - 1 0 Ararukiruamino group is intended to mean a structure in which -NH- and C 7 _ 1 0 Ararukiru groups are combined, for example, Benjiruamino group, phenylpropyl E chill ⁇ amino group can be mentioned up.
- Heteroaryl group means pyridyl group, thiazolyl group, isothiazolyl group, thiadiazolyl group, pyrazolyl group, imidazolyl group, furyl group (including 2-furyl group and 3-furyl group), chenyl group (2-phenyl group, 3-phenyl group).
- “4- to 6-membered heterocycloalkyl group” refers to a 4- to 6-membered heterocycloalkyl group containing at least one hetero atom (oxygen, nitrogen or sulfur atom) in the ring. Examples thereof include a cyclic amino group having one or more nitrogen atoms in the ring, and optionally having one or more oxygen atoms and sulfur atoms. Examples include a morpholino group, a piberidinyl group, a piperazinyl group, a 1-pyrrolidinyl group and the like.
- 0 ⁇ 6 thiazolyl group substituted with an alkyl group means that at least one hydrogen atom is an alkyl group on the ring, preferably 0 DOO 4 alkyl group, more preferably thiazolyl group had it occurred substituted methyl group And examples thereof include a 4-methylthiazole-12-yl group.
- 0 ⁇ 6-pyridyl group substituted with an alkyl group means that at least one hydrogen atom is an alkyl group on the ring, preferably - 4 alkyl group, more preferably menu It is a pyridyl group substituted by a tyl group, and examples thereof include a 2-methylpyridine-15-yl group.
- ( ⁇ _ 6 alkyl pyrazolyl group substituted with group) at least one hydrogen atom is an alkyl group on the ring, preferably an alkyl group, more preferably a methyl group, a pyrazolyl group substituted with Echiru group Examples thereof include a 1-methylpyrazole-4-yl group and a 1-ethylpyrazole-4-yl group.
- Pyrrolyl group substituted with an alkyl group "means that at least one hydrogen atom is an alkyl group on the ring, preferably - is 4 alkyl group, more preferably by the methylation based connexion substituted pin hole drill group Examples thereof include a 1-methylpyrrolyl group.
- 4-1-6 alkylpiperazinyl group refers to a 1-piperazinyl group in which a hydrogen atom on one nitrogen atom is substituted with a 6- alkyl group, for example, 4-methylpiperazine-1-yl group, 4-ethyl Piperazine-11-yl group and the like. More preferred embodiments of the compound of the present invention are described below.
- Preferred examples of X are: 1 (CH 2 ) n — (n is an integer of 0 to 3), —CO (CH 2 ) n — (n is an integer of 0 to 3), -CONH (CH 2 ) n-, where n is an integer from 0-3.
- X are —CH 2 —, one CO (CH 2 ) n- (n is an integer of 0-2).
- R 40 , R 41 , R 42 , R 43 and R 44 are the same or different and include a hydrogen atom; a halogen atom; a hydroxyl group; a halogen atom and a hydroxyl group. C optionally substituted with 1 to 4 substituents selected from the group
- m ' is an integer of 0- 4
- Q' is nitro group which can be substituted by 1-4 halogen atom C alkoxy group; alkoxy ⁇ - 6 alkoxy Groups; C 2 - 1Q Ashiruokishi groups; C 2 - 1 () Ashirire groups; C 2 - 6 alkoxycarbonyl group; CI- 6 alkylthio; C!
- alkylsulfinyl group C 6 alkylsulfonyl group; C 2 _ 10 acylamino group; ⁇ 6 alkylsulfonylamino group; rubamoyl group; N, N-di-6 alkyl) amino group; —Di-6alkyl) is an aminocarbonyl group ⁇ ; or
- R 41 , R 42 , R 43 and R 44 are the same or different and each are a hydrogen atom; a halogen atom; a hydroxyl group; and 14 substituents selected from the group consisting of a halogen atom and a hydroxyl group.
- m is an integer of 0-4, Q, is a nitro group; may be substituted with 1-4 halogen atoms; an alkoxy group; a C- 6 alkoxyalkoxy group; An acyloxy group; A C 2 _ 6 alkoxycarbonyl group; a C 2 _ 10 acylamino group; a 6 alkylsulfonylamino group; or a carbamoyl group ⁇ ;
- reaction of the present invention is performed by various known glycosylation reactions shown in Reference Examples below. The fact that the i3-selective reaction is superior to the 5-thio-glycosylation reaction when the conditions are used will be explained.
- a 1 _0-sulfonyl derivative was prepared from 2,3,4,6-tetratetraacetyl-5-thio D-dalcopyranose (7) and tried to react with 2- (4-ethylbenzyl) phenol (9). The desired product (10) was not obtained.
- the present invention it has become possible to provide a method for selectively chemically synthesizing an aryl 1,2-trans-5-thioglycoside bond (/ 3-5-thiodaricoside). According to the method of the present invention, it is possible to provide a method of producing an aryl-5-thio / 3-D-aldodexopyranoside derivative or a synthetic intermediate thereof useful as an SGLT2 inhibitor.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
Description
Claims
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA20041210074A UA77300C2 (en) | 2002-08-09 | 2003-08-08 | 5-thio-?-d-glucopyranoside derivatives and pharmaceutical composition for treating diabetes |
| CA002493491A CA2493491A1 (en) | 2002-08-09 | 2003-08-08 | Process for selective production of aryl 5-thio-.beta.-d-aldohexopyranosides |
| JP2004527382A JPWO2004014930A1 (ja) | 2002-08-09 | 2003-08-08 | 選択的なアリール5−チオ−β−D−アルドヘキソピラノシドの製造法 |
| HK05111661.0A HK1079532B (en) | 2002-08-09 | 2003-08-08 | PROCESS FOR SELECTIVE PRODUCTION OF ARYL 5-THIO-β-D-ALDOHEXOPYRANOSIDES |
| US10/521,809 US7250522B2 (en) | 2002-08-09 | 2003-08-08 | Method for selective preparation of aryl 5-thio-β-D-aldohexopyranosides |
| AU2003254903A AU2003254903B9 (en) | 2002-08-09 | 2003-08-08 | Method for selective preparation of aryl 5-thio-beta-D-aldohexopyranosides |
| MXPA05000725A MXPA05000725A (es) | 2002-08-09 | 2003-08-08 | Procedimiento para la produccion selectiva de aril-5-tio-??-d-aldohexopiranosidos. |
| EP03784622A EP1541578A1 (en) | 2002-08-09 | 2003-08-08 | Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides |
| KR1020047014192A KR100588457B1 (ko) | 2002-08-09 | 2003-08-08 | 아릴 5-티오-β-D-글루코피라노시드 유도체 및 이를함유하는 당뇨병 치료약 |
| ZA200407187A ZA200407187B (en) | 2002-08-09 | 2004-09-08 | Aryl 5-thio-beta-D-glucopyranoside derivatives andtherapeutic agents for diabetes containing the sa me. |
| NO20050650A NO20050650L (no) | 2002-08-09 | 2005-02-07 | Fremgangsmate for selektiv fremstilling av aryl-5-tio- -D-aldoheksopyranosider |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002-233015 | 2002-08-09 | ||
| JP2002233015 | 2002-08-09 | ||
| JP2003-97839 | 2003-04-01 | ||
| JP2003097839 | 2003-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004014930A1 true WO2004014930A1 (ja) | 2004-02-19 |
Family
ID=31719867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2003/010159 Ceased WO2004014930A1 (ja) | 2002-08-09 | 2003-08-08 | 選択的なアリール5−チオ−β−D−アルドヘキソピラノシドの製造法 |
| PCT/JP2003/010160 Ceased WO2004014931A1 (ja) | 2002-08-09 | 2003-08-08 | アリール5−チオ−β−D−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2003/010160 Ceased WO2004014931A1 (ja) | 2002-08-09 | 2003-08-08 | アリール5−チオ−β−D−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7414072B2 (ja) |
| EP (2) | EP1541578A1 (ja) |
| JP (2) | JPWO2004014930A1 (ja) |
| KR (2) | KR100588457B1 (ja) |
| CN (2) | CN1312165C (ja) |
| AU (2) | AU2003254903B9 (ja) |
| BR (1) | BR0310006A (ja) |
| CA (2) | CA2478889A1 (ja) |
| HR (1) | HRP20040814A2 (ja) |
| MX (2) | MXPA04009265A (ja) |
| NO (2) | NO20043733L (ja) |
| NZ (1) | NZ535229A (ja) |
| PL (2) | PL375298A1 (ja) |
| RU (1) | RU2322449C2 (ja) |
| TW (2) | TWI274055B (ja) |
| UA (1) | UA77300C2 (ja) |
| WO (2) | WO2004014930A1 (ja) |
| ZA (1) | ZA200407187B (ja) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004043471A1 (ja) * | 2002-11-13 | 2004-05-27 | Taisho Pharmaceutical Co., Ltd. | 鎮痒剤 |
| JPWO2004089967A1 (ja) * | 2003-04-01 | 2006-07-06 | 大正製薬株式会社 | ヘテロアリール5−チオ−β−D−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬 |
| WO2006073197A1 (ja) * | 2005-01-07 | 2006-07-13 | Taisho Pharmaceutical Co., Ltd. | 1-チオ-d-グルシトール誘導体 |
| WO2008001864A1 (en) * | 2006-06-29 | 2008-01-03 | Taisho Pharmaceutical Co., Ltd. | C-phenyl 1-thioglucitol compound |
| US9061060B2 (en) | 2008-07-15 | 2015-06-23 | Theracos Inc. | Deuterated benzylbenzene derivatives and methods of use |
| WO2015125572A1 (ja) * | 2014-02-19 | 2015-08-27 | 富士フイルム株式会社 | チオピラノース化合物およびその製造方法 |
| US9884882B2 (en) | 2014-02-18 | 2018-02-06 | Fujifilm Corporation | Method for producing thiolane skeleton-type glycoconjugate, and thiolane skeleton-type glycoconjugate |
| US9896471B2 (en) | 2012-03-28 | 2018-02-20 | Fujifilm Corporation | Salt of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine |
| US10059734B2 (en) | 2014-10-31 | 2018-08-28 | Fujifilm Corporation | Thionucleoside derivative or salt thereof, and pharmaceutical composition |
| US10093645B2 (en) | 2012-08-13 | 2018-10-09 | Fujifilm Corporation | Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same |
| US11141421B2 (en) | 2018-01-29 | 2021-10-12 | Fujifilm Corporation | Antitumor agent for biliary tract cancer and method for treating biliary tract cancer |
| US11369625B2 (en) | 2016-08-31 | 2022-06-28 | Fujifilm Corporation | Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
| RS53365B (sr) | 2003-08-01 | 2014-10-31 | Mitsubishi Tanabe Pharma Corporation | Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavisan od natrijuma |
| US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
| TW200606129A (en) * | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
| ZA200700755B (en) * | 2004-07-26 | 2009-05-27 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes |
| TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
| TWI365186B (en) | 2005-01-31 | 2012-06-01 | Mitsubishi Tanabe Pharma Corp | Indole derivatives |
| JP5073948B2 (ja) * | 2005-01-31 | 2012-11-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
| EP1854806A1 (en) * | 2006-05-02 | 2007-11-14 | MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Thioglycosides as pharmaceutically active agents |
| JP2009167104A (ja) * | 2006-05-02 | 2009-07-30 | Taisho Pharmaceutical Co Ltd | フェニル5−チオグリコシド化合物 |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| US7803778B2 (en) * | 2006-05-23 | 2010-09-28 | Theracos, Inc. | Glucose transport inhibitors and methods of use |
| TWI418556B (zh) | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
| FR2906247B1 (fr) * | 2006-09-27 | 2008-12-26 | Fournier S A Sa Lab | Nouveaux derives de 5-thioxylopyranose |
| TWI499414B (zh) * | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法 |
| MX2009003927A (es) * | 2006-10-13 | 2009-04-23 | Chugai Pharmaceutical Co Ltd | Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes. |
| CN101611032B (zh) | 2006-12-04 | 2012-07-18 | 詹森药业有限公司 | 作为抗糖尿病药的含噻吩基的吡喃葡糖基衍生物 |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| CN101611023A (zh) | 2006-12-14 | 2009-12-23 | 大正制药株式会社 | 1-苯基1-硫代-d-山梨醇衍生物 |
| US7795228B2 (en) * | 2006-12-28 | 2010-09-14 | Theracos, Inc. | Spiroheterocyclic glycosides and methods of use |
| WO2008109591A1 (en) * | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
| US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
| US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
| AU2008232419B2 (en) | 2007-04-02 | 2013-06-20 | Theracos, Inc. | Benzylic glycoside derivatives and methods of use |
| UA107175C2 (uk) * | 2007-07-26 | 2014-12-10 | Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти | |
| UA99924C2 (en) * | 2007-08-23 | 2012-10-25 | Теракос, Инк. | Benzylbenzol derivatives and using thereof |
| NO2200606T3 (ja) | 2007-09-10 | 2018-03-24 | ||
| UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
| SMT201600475T1 (it) | 2008-08-22 | 2017-03-08 | Theracos Sub Llc | Procedimenti per la preparazione di inibitori di sglt2. |
| WO2010023594A1 (en) * | 2008-08-28 | 2010-03-04 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| JP5658751B2 (ja) | 2009-07-10 | 2015-01-28 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | 1−(β−D−グルコピラノシル)−4−メチル−3−[5−(4−フルオロフェニル)−2−チエニルメチル]ベンゼンのための結晶化方法 |
| PL2488515T3 (pl) | 2009-10-14 | 2017-07-31 | Janssen Pharmaceutica Nv | Sposób wytwarzania związków użytecznych jako inhibitory sglt2 |
| EA021983B1 (ru) | 2009-11-02 | 2015-10-30 | Пфайзер Инк. | Производные диоксабицикло[3.2.1]октан-2,3,4-триола |
| LT2568988T (lt) | 2010-05-11 | 2016-09-12 | Janssen Pharmaceutica, N.V. | Farmacinės kompozicijos, apimančios 1-(beta-d-gliukopiranozil)-2-tienilmetilbenzeno darinius kaip sglt inhibitorius |
| WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| KR101913587B1 (ko) | 2011-04-13 | 2018-10-31 | 얀센 파마슈티카 엔.브이. | Sglt2의 억제제로서 유용한 화합물의 제조 방법 |
| TWI542596B (zh) | 2011-05-09 | 2016-07-21 | 健生藥品公司 | (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體 |
| US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
| JP6433974B2 (ja) | 2013-03-14 | 2018-12-05 | トレロ ファーマシューティカルズ, インコーポレイテッド | Jak2およびalk2阻害剤およびその使用方法 |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PT2981271T (pt) | 2013-04-05 | 2019-02-19 | Boehringer Ingelheim Int | Utilizações terapêuticas de empagliflozina |
| HK1213818A1 (zh) | 2013-04-05 | 2016-07-15 | 勃林格殷格翰国际有限公司 | 依帕列净的治疗用途 |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| SI2986304T1 (sl) | 2013-04-18 | 2022-04-29 | Boehringer Ingelheim International Gmbh | Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe |
| CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
| US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
| CN109922813A (zh) | 2016-11-10 | 2019-06-21 | 勃林格殷格翰国际有限公司 | 药物组合物、治疗方法及其用途 |
| AU2019310590A1 (en) | 2018-07-26 | 2021-01-14 | Sumitomo Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10237089A (ja) * | 1996-12-26 | 1998-09-08 | Tanabe Seiyaku Co Ltd | プロピオフェノン誘導体及びその製法 |
| WO2001016147A1 (en) * | 1999-08-31 | 2001-03-08 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| WO2001068660A1 (en) * | 2000-03-17 | 2001-09-20 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
| WO2001074834A1 (en) * | 2000-03-30 | 2001-10-11 | Bristol-Myers Squibb Company | O-aryl glucoside sglt2 inhibitors and method |
| WO2001074835A1 (en) * | 2000-03-30 | 2001-10-11 | Bristol-Myers Squibb Company | O-glucosylated benzamide sglt2 inhibitors and method |
| WO2002036602A1 (en) * | 2000-11-02 | 2002-05-10 | Ajinomoto Co., Inc. | Novel pyrazole derivatives and diabetes remedies containing the same |
| WO2002053573A1 (en) * | 2000-12-28 | 2002-07-11 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2660313B1 (fr) * | 1990-04-02 | 1992-07-03 | Fournier Ind & Sante | Nouveau sulfonyl-phenyl-betha-d-thioxylosides, leur procede de preparation et leur utilisation en therapeutique. |
| PT850948E (pt) | 1996-12-26 | 2002-08-30 | Tanabe Seiyaku Co | Derivados propiofenona e processo para a preparacao dos mesmos |
| FR2801055B1 (fr) * | 1999-11-17 | 2002-02-08 | Fournier Ind & Sante | Derives de beta-d-5-thioxylose, procede de preparation et utilisation en therapeutique |
| WO2001090269A1 (de) | 2000-05-20 | 2001-11-29 | Tesa Ag | Verwendung eines hochdichten papierträgers als trägerbahn in einem abdeckmaterial für ein klebeband |
| CN1293087C (zh) * | 2000-09-29 | 2007-01-03 | 橘生药品工业株式会社 | 吡喃葡糖氧基苄基苯衍生物及其药物组合物 |
| KR100882179B1 (ko) | 2001-06-20 | 2009-02-06 | 깃세이 야쿠힌 고교 가부시키가이샤 | 함질소 복소환 유도체, 그것을 함유하는 의약 조성물, 그의약 용도 및 그 제조 중간체 |
| CN1761676A (zh) * | 2003-04-01 | 2006-04-19 | 大正制药株式会社 | 杂芳基5-硫代-β-D-吡喃葡糖苷衍生物及含有该衍生物的糖尿病治疗药 |
| JPWO2004089967A1 (ja) | 2003-04-01 | 2006-07-06 | 大正製薬株式会社 | ヘテロアリール5−チオ−β−D−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬 |
-
2003
- 2003-08-08 RU RU2004135914/04A patent/RU2322449C2/ru not_active IP Right Cessation
- 2003-08-08 AU AU2003254903A patent/AU2003254903B9/en not_active Ceased
- 2003-08-08 JP JP2004527382A patent/JPWO2004014930A1/ja not_active Ceased
- 2003-08-08 TW TW092121886A patent/TWI274055B/zh not_active IP Right Cessation
- 2003-08-08 WO PCT/JP2003/010159 patent/WO2004014930A1/ja not_active Ceased
- 2003-08-08 PL PL03375298A patent/PL375298A1/xx not_active Application Discontinuation
- 2003-08-08 UA UA20041210074A patent/UA77300C2/uk unknown
- 2003-08-08 PL PL03372865A patent/PL372865A1/xx not_active Application Discontinuation
- 2003-08-08 KR KR1020047014192A patent/KR100588457B1/ko not_active Expired - Fee Related
- 2003-08-08 JP JP2004527383A patent/JP3813160B2/ja not_active Expired - Fee Related
- 2003-08-08 CN CNB038056402A patent/CN1312165C/zh not_active Expired - Fee Related
- 2003-08-08 US US10/518,788 patent/US7414072B2/en not_active Expired - Fee Related
- 2003-08-08 EP EP03784622A patent/EP1541578A1/en not_active Withdrawn
- 2003-08-08 US US10/521,809 patent/US7250522B2/en not_active Expired - Fee Related
- 2003-08-08 MX MXPA04009265A patent/MXPA04009265A/es active IP Right Grant
- 2003-08-08 CA CA002478889A patent/CA2478889A1/en not_active Abandoned
- 2003-08-08 CA CA002493491A patent/CA2493491A1/en not_active Abandoned
- 2003-08-08 CN CNB038191423A patent/CN100341885C/zh not_active Expired - Fee Related
- 2003-08-08 TW TW092121895A patent/TW200409778A/zh unknown
- 2003-08-08 EP EP03784623A patent/EP1528066A4/en not_active Withdrawn
- 2003-08-08 BR BR0310006-5A patent/BR0310006A/pt not_active IP Right Cessation
- 2003-08-08 WO PCT/JP2003/010160 patent/WO2004014931A1/ja not_active Ceased
- 2003-08-08 HR HR20040814A patent/HRP20040814A2/hr not_active Application Discontinuation
- 2003-08-08 NZ NZ535229A patent/NZ535229A/en unknown
- 2003-08-08 MX MXPA05000725A patent/MXPA05000725A/es active IP Right Grant
- 2003-08-08 KR KR1020057002280A patent/KR20050056194A/ko not_active Ceased
- 2003-08-08 AU AU2003254904A patent/AU2003254904A1/en not_active Abandoned
-
2004
- 2004-09-07 NO NO20043733A patent/NO20043733L/no not_active Application Discontinuation
- 2004-09-08 ZA ZA200407187A patent/ZA200407187B/en unknown
-
2005
- 2005-02-07 NO NO20050650A patent/NO20050650L/no not_active Application Discontinuation
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10237089A (ja) * | 1996-12-26 | 1998-09-08 | Tanabe Seiyaku Co Ltd | プロピオフェノン誘導体及びその製法 |
| WO2001016147A1 (en) * | 1999-08-31 | 2001-03-08 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| WO2001068660A1 (en) * | 2000-03-17 | 2001-09-20 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
| WO2001074834A1 (en) * | 2000-03-30 | 2001-10-11 | Bristol-Myers Squibb Company | O-aryl glucoside sglt2 inhibitors and method |
| WO2001074835A1 (en) * | 2000-03-30 | 2001-10-11 | Bristol-Myers Squibb Company | O-glucosylated benzamide sglt2 inhibitors and method |
| WO2002036602A1 (en) * | 2000-11-02 | 2002-05-10 | Ajinomoto Co., Inc. | Novel pyrazole derivatives and diabetes remedies containing the same |
| WO2002053573A1 (en) * | 2000-12-28 | 2002-07-11 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
Non-Patent Citations (3)
| Title |
|---|
| BOZO, E. ET AL: "Synthesis of 4-cyanophenyl and 4-cyanophenyl and 4-nitrophenyl 1,5-dithio-L- and -D-arabinopyranosides posessing antithrombotic activity", CARBOHYDRATE RESEARCH, vol. 311, 1998, pages 191 - 202, XP004141931 * |
| RANDELL, K.D. ET AL: "Synthesis and glycosides inhibitory activity of 5-thioglucopyranosylamines. Molecular modeling of complexes with glucoamilase", CARBOHYDRATE RESEARCH, vol. 321, pages 143 - 156, XP004362858 * |
| YUASA, H. ET AL: "Relative Nucleophilicity of the two sulfur atoms in 1,5-Dithioglucopyranoside", ANGEW. CHEM. INT. ED. ENGL., vol. 36, no. 8, 1997, pages 868 - 870, XP002973598 * |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004043471A1 (ja) * | 2002-11-13 | 2004-05-27 | Taisho Pharmaceutical Co., Ltd. | 鎮痒剤 |
| JPWO2004089967A1 (ja) * | 2003-04-01 | 2006-07-06 | 大正製薬株式会社 | ヘテロアリール5−チオ−β−D−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬 |
| CN101103013B (zh) * | 2005-01-07 | 2012-05-23 | 大正制药株式会社 | 1-硫代-d-葡萄糖醇衍生物 |
| WO2006073197A1 (ja) * | 2005-01-07 | 2006-07-13 | Taisho Pharmaceutical Co., Ltd. | 1-チオ-d-グルシトール誘導体 |
| EP1845095A4 (en) * | 2005-01-07 | 2008-06-25 | Taisho Pharmaceutical Co Ltd | 1-thio-D-GLUCITOLDERIVATE |
| JPWO2006073197A1 (ja) * | 2005-01-07 | 2008-08-07 | 大正製薬株式会社 | 1−チオ−d−グルシトール誘導体 |
| JP2010059173A (ja) * | 2005-01-07 | 2010-03-18 | Taisho Pharmaceutical Co Ltd | 1−チオ−d−グルシトール誘導体 |
| JP4492968B2 (ja) * | 2005-01-07 | 2010-06-30 | 大正製薬株式会社 | 1−チオ−d−グルシトール誘導体 |
| US7910619B2 (en) | 2005-01-07 | 2011-03-22 | Taisho Pharmaceutical Co., Ltd. | 1-thio-D-glucitol derivatives |
| US8017792B2 (en) | 2005-01-07 | 2011-09-13 | Taisho Pharmaceutical Co., Ltd. | 1-thio-D-glucitol derivatives |
| CN101479254B (zh) * | 2006-06-29 | 2012-05-30 | 大正制药株式会社 | C-苯基1-硫代山梨醇化合物 |
| US8115017B2 (en) | 2006-06-29 | 2012-02-14 | Taisho Pharmaceutical Co., Ltd | C-phenyl 1-thioglucitol compound |
| RU2434862C2 (ru) * | 2006-06-29 | 2011-11-27 | Тайсо Фармасьютикал Ко., Лтд. | С-фенил-1-тиоглюцитолы |
| WO2008001864A1 (en) * | 2006-06-29 | 2008-01-03 | Taisho Pharmaceutical Co., Ltd. | C-phenyl 1-thioglucitol compound |
| JP5152519B2 (ja) * | 2006-06-29 | 2013-02-27 | 大正製薬株式会社 | C−フェニル1−チオグルシト−ル化合物 |
| US9061060B2 (en) | 2008-07-15 | 2015-06-23 | Theracos Inc. | Deuterated benzylbenzene derivatives and methods of use |
| US9896471B2 (en) | 2012-03-28 | 2018-02-20 | Fujifilm Corporation | Salt of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine |
| US10570112B2 (en) | 2012-08-13 | 2020-02-25 | Fujifilm Corporation | Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same |
| US10093645B2 (en) | 2012-08-13 | 2018-10-09 | Fujifilm Corporation | Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same |
| US9884882B2 (en) | 2014-02-18 | 2018-02-06 | Fujifilm Corporation | Method for producing thiolane skeleton-type glycoconjugate, and thiolane skeleton-type glycoconjugate |
| WO2015125572A1 (ja) * | 2014-02-19 | 2015-08-27 | 富士フイルム株式会社 | チオピラノース化合物およびその製造方法 |
| JP2015155380A (ja) * | 2014-02-19 | 2015-08-27 | 富士フイルム株式会社 | チオピラノース化合物およびその製造方法 |
| US9815812B2 (en) | 2014-02-19 | 2017-11-14 | Fujifilm Corporation | Thiopyranose compound and method for producing same |
| US10385089B2 (en) | 2014-10-31 | 2019-08-20 | Fujifilm Corporation | Thionucleoside derivative or salt thereof, and pharmaceutical composition |
| US10059734B2 (en) | 2014-10-31 | 2018-08-28 | Fujifilm Corporation | Thionucleoside derivative or salt thereof, and pharmaceutical composition |
| US11369625B2 (en) | 2016-08-31 | 2022-06-28 | Fujifilm Corporation | Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit |
| US11141421B2 (en) | 2018-01-29 | 2021-10-12 | Fujifilm Corporation | Antitumor agent for biliary tract cancer and method for treating biliary tract cancer |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004014930A1 (ja) | 選択的なアリール5−チオ−β−D−アルドヘキソピラノシドの製造法 | |
| JP4249256B2 (ja) | ベンジルフェニルグルコピラノシド誘導体 | |
| AU2004260760B2 (en) | Novel compounds | |
| CN101103013B (zh) | 1-硫代-d-葡萄糖醇衍生物 | |
| CA2402609C (en) | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | |
| MXPA06005106A (es) | 4-biarilil-1-fenilazetidin-2-onas. | |
| CN101495495A (zh) | 取代螺缩酮衍生物、及其作为糖尿病治疗药的应用 | |
| KR102124109B1 (ko) | C말단 hsp90 억제제 | |
| JP2009203230A (ja) | ベンジルフェニルグルコピラノシド誘導体を含有する医薬組成物 | |
| CN107406478A (zh) | 半乳糖凝集素的α‑D‑半乳糖苷抑制剂 | |
| JP2005247834A (ja) | ナトリウム依存性グルコース供輸送体2の活性阻害剤 | |
| CN101010276B (zh) | 环己烷衍生物、其前体药物及其盐、以及含有它的糖尿病治疗药 | |
| HK1077582B (en) | ARYL 5-THIO-β-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME | |
| HK1130063A (en) | Substituted spiroketal derivative and use thereof as drug for treating diabetes | |
| TW201300394A (zh) | C-芳基葡萄糖苷衍生物、其製備方法及其在醫藥上的應用 | |
| HK1124615A (en) | Benzyl phenyl glucopyranoside derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 3086/CHENP/2004 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003254903 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/000725 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2493491 Country of ref document: CA Ref document number: 2004527382 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10521809 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003784622 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 20038191423 Country of ref document: CN Ref document number: 1020057002280 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 375298 Country of ref document: PL |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020057002280 Country of ref document: KR |
|
| WWP | Wipo information: published in national office |
Ref document number: 2003784622 Country of ref document: EP |